Oyster Point Pharma Management
Management criteria checks 4/4
Key information
Jeff Nau
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 20.1% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.1yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Nov 08
Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
Aug 17Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 14Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating
Jul 18Oyster Therapeutics: State Of Business Is Confounding
Jun 30Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Dec 24Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans
Oct 15Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study
Jun 21Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation
May 10Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares
Feb 09
Oyster Point Pharma files US application for its lead program in dry eye disease
Dec 18Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth
Dec 18Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$177m |
| Jun 30 2022 | n/a | n/a | -US$158m |
| Mar 31 2022 | n/a | n/a | -US$130m |
| Dec 31 2021 | US$3m | US$563k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$81m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$6m | US$530k | -US$71m |
| Sep 30 2020 | n/a | n/a | -US$68m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$4m | US$390k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$390k | US$300k | -US$17m |
Compensation vs Market: Jeff's total compensation ($USD2.80M) is about average for companies of similar size in the US market ($USD2.86M).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
CEO
Jeff Nau (47 yo)
5.3yrs
Tenure
US$2,803,339
Compensation
Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$2.80m | 0.31% $ 933.1k | |
| CFO & Chief Business Officer | 3.5yrs | US$1.88m | 0.20% $ 605.7k | |
| Senior VP of CMC & Operations | 2.2yrs | no data | no data | |
| Chief Scientific Officer | 2.1yrs | no data | no data | |
| VP of Investor relations | no data | no data | no data | |
| Senior VP & General Counsel | 1.2yrs | no data | no data | |
| Chief Compliance & Privacy Officer | 1.2yrs | no data | no data | |
| Vice President of Communications & Public Relations | less than a year | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.2yrs | no data | no data | |
| Chief Medical Officer of Medical Affairs | 2.1yrs | no data | no data | |
| Senior VP & Head of Commercial | less than a year | no data | no data |
2.1yrs
Average Tenure
Experienced Management: OYST's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$2.80m | 0.31% $ 933.1k | |
| Independent Director | 2.3yrs | US$176.43k | 0.048% $ 144.8k | |
| Independent Director | 5.5yrs | US$207.32k | 0.037% $ 112.4k | |
| Independent Director | 3.3yrs | US$167.49k | 0.12% $ 370.7k | |
| Non-Executive Chairperson | 1.5yrs | US$354.47k | 0.012% $ 35.5k | |
| Director | 5.3yrs | US$158.56k | 0.44% $ 1.3m | |
| Independent Director | 3.9yrs | US$171.43k | 0.037% $ 112.4k | |
| Independent Director | 3.9yrs | US$167.71k | 0.041% $ 123.6k | |
| Independent Director | 1.8yrs | US$553.37k | 0.043% $ 131.4k |
3.9yrs
Average Tenure
52.5yo
Average Age
Experienced Board: OYST's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/04 22:32 |
| End of Day Share Price | 2022/12/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oyster Point Pharma, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |
| Anupam Rama | J.P. Morgan |